Show simple item record

dc.contributor.authorFais, S.en_US
dc.contributor.authorO'Driscoll, L.en_US
dc.contributor.authorBorras, F. E.en_US
dc.contributor.authorBuzas, E.en_US
dc.contributor.authorCamussi, G.en_US
dc.contributor.authorCappello, F.en_US
dc.contributor.authorCarvalho, J.en_US
dc.contributor.authorCordeiro Da Silva, A.en_US
dc.contributor.authorDel Portillo, H.en_US
dc.contributor.authorEl Andaloussi, S.en_US
dc.contributor.authorFicko Trček, T.en_US
dc.contributor.authorFurlan, R.en_US
dc.contributor.authorHendrix, A.en_US
dc.contributor.authorGursel, I.en_US
dc.contributor.authorKralj-Iglic, V.en_US
dc.contributor.authorKaeffer, B.en_US
dc.contributor.authorKosanovic, M.en_US
dc.contributor.authorLekka, M. E.en_US
dc.contributor.authorLipps, G.en_US
dc.contributor.authorLogozzi, M.en_US
dc.contributor.authorMarcilla, A.en_US
dc.contributor.authorSammar, M.en_US
dc.contributor.authorLlorente, A.en_US
dc.contributor.authorNazarenko, I.en_US
dc.contributor.authorOliveira, C.en_US
dc.contributor.authorPocsfalvi, G.en_US
dc.contributor.authorRajendran, L.en_US
dc.contributor.authorRaposo, G.en_US
dc.contributor.authorRohde, E.en_US
dc.contributor.authorSiljander, P.en_US
dc.contributor.authorVan, N. G.en_US
dc.contributor.authorVasconcelos, M. H.en_US
dc.contributor.authorYáñez-Mó, M.en_US
dc.contributor.authorYliperttula, M. L.en_US
dc.contributor.authorZarovni, N.en_US
dc.contributor.authorZavec, A. B.en_US
dc.contributor.authorGiebel, B.en_US
dc.date.accessioned2018-04-12T13:46:04Z
dc.date.available2018-04-12T13:46:04Z
dc.date.issued2016-03en_US
dc.identifier.issn1936-0851
dc.identifier.urihttp://hdl.handle.net/11693/38156
dc.description.abstractRecent research has demonstrated that all body fluids assessed contain substantial amounts of vesicles that range in size from 30 to 1000 nm and that are surrounded by phospholipid membranes containing different membrane microdomains such as lipid rafts and caveolae. The most prominent representatives of these so-called extracellular vesicles (EVs) are nanosized exosomes (70-150 nm), which are derivatives of the endosomal system, and microvesicles (100-1000 nm), which are produced by outward budding of the plasma membrane. Nanosized EVs are released by almost all cell types and mediate targeted intercellular communication under physiological and pathophysiological conditions. Containing cell-type-specific signatures, EVs have been proposed as biomarkers in a variety of diseases. Furthermore, according to their physical functions, EVs of selected cell types have been used as therapeutic agents in immune therapy, vaccination trials, regenerative medicine, and drug delivery. Undoubtedly, the rapidly emerging field of basic and applied EV research will significantly influence the biomedicinal landscape in the future. In this Perspective, we, a network of European scientists from clinical, academic, and industry settings collaborating through the H2020 European Cooperation in Science and Technology (COST) program European Network on Microvesicles and Exosomes in Health and Disease (ME-HAD), demonstrate the high potential of nanosized EVs for both diagnostic and therapeutic (i.e., theranostic) areas of nanomedicine.en_US
dc.language.isoEnglishen_US
dc.source.titleACS Nanoen_US
dc.relation.isversionofhttps://doi.org/10.1021/acsnano.5b08015en_US
dc.subjectCell membranesen_US
dc.subjectInternational cooperationen_US
dc.subjectMedical nanotechnologyen_US
dc.subjectPhospholipidsen_US
dc.subjectProgram diagnosticsen_US
dc.subjectIntercellular communicationsen_US
dc.subjectMembrane microdomainsen_US
dc.subjectPathophysiologicalen_US
dc.subjectPhospholipid membraneen_US
dc.subjectRecent researchesen_US
dc.subjectRegenerative medicineen_US
dc.subjectScience and Technologyen_US
dc.subjectTherapeutic agentsen_US
dc.subjectDiagnosisen_US
dc.subjectAnimalen_US
dc.subjectCell communicationen_US
dc.subjectClinical trial (topic)en_US
dc.subjectDrug delivery systemen_US
dc.subjectExosomeen_US
dc.subjectHumanen_US
dc.subjectMembrane microparticleen_US
dc.subjectNanomedicineen_US
dc.subjectPhysiologyen_US
dc.subjectTheranostic nanomedicineen_US
dc.subjectAnimalsen_US
dc.subjectCell Communicationen_US
dc.subjectCell-Derived Microparticlesen_US
dc.subjectClinical Trials as Topicen_US
dc.subjectDrug Delivery Systemsen_US
dc.subjectExosomesen_US
dc.subjectExtracellular Vesiclesen_US
dc.subjectHumansen_US
dc.subjectNanomedicineen_US
dc.subjectTheranostic Nanomedicineen_US
dc.titleEvidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicineen_US
dc.typeReviewen_US
dc.departmentDepartment of Molecular Biology and Geneticsen_US
dc.citation.spage3886en_US
dc.citation.epage3899en_US
dc.citation.volumeNumber10en_US
dc.citation.issueNumber4en_US
dc.identifier.doi10.1021/acsnano.5b08015en_US
dc.publisherAmerican Chemical Societyen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record